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Abstract The experimental autoimmune encephalitis (EAE)
model is used for preclinical research into the pathogenesis of
multiple sclerosis (MS), mostly in inbred, specific pathogen
free (SPF)-raised laboratory mice. However, the naive state of
the laboratory mouse immune system is considered a major
hurdle in the translation of principles from the EAE model to
the MS patient. Non-human primates (NHP) have an immune
system harboring T- and B-cell memory against environmen-
tal antigens, similar as in humans. We sought to further refine
existing NHP EAE models, which may help to bridge the gab
between mouse EAE models and MS. We report here on new
EAE models in three NHP species: rhesus monkeys (Macaca
mulatta), cynomolgus monkeys (Macaca fascicularis) and
common marmosets (Callithrix jacchus). EAE was induced
with recombinant human myelin oligodendrocyte glycopro-
tein extracellular domain (1–125) (rhMOG) formulated in
incomplete Freund’s adjuvant (IFA). IFA lacks the bacterial
antigens that are present in complete Freund’s adjuvant
(CFA), which are notorious for the induction of discomforting
side effects. Clinically evident EAE could be induced in two
out of five rhesus monkeys, six out of six cynomolgus mon-
keys and six out of six common marmosets. In each of these
species, the presence of an early, high anti-rhMOG IgM
response is correlated with EAE with an earlier onset and
more severe disease course. Animals without an early high
IgM response either did not develop disease (rhesus monkeys)
or developed only mild signs of neurological deficit (marmo-
set and cynomolgus monkeys).
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Introduction
Experimental autoimmune encephalomyelitis (EAE) is
the primary animal model of the human autoimmune
neuroinflammatory disease multiple sclerosis (MS) (Hohlfeld
and Wekerle 2004; Gold et al. 2006). EAE is also widely used
as a generic animal model for autoimmunity, tolerance,
and T helper subset function, notably Th1 and Th17.
The validity of the EAE model for translational research
into immunopathogenic mechanisms of MS and for the de-
velopment of new treatments is often criticized, as in many
cases experimental therapies effective in EAE models fail in
MS patients (Sriram and Steiner 2005; Ransohoff 2006).
One of the fundamental differences between humans and
inbred, specific pathogen free (SPF)-raised laboratory mice
is that the immune system of these mice is essentially naive,
while the human immune system receives continuous edu-
cation by the daily encounter with foreign antigens (Sriram
and Steiner 2005). Non-human primates (NHP) also have an
antigen-experienced immune system, more closely resem-
bling the human immune system than rodents do (Pitcher
et al. 2002; Magalhaes et al. 2010).
A frequently expressed concern on the EAE model is the
highly artificial way the disease is induced, i.e. via intradermal
or subcutenaous injection of myelin antigen formulated in
strong bacterial adjuvants such as complete Freund’s adjuvant
(CFA) (Sriram and Steiner 2005; Ransohoff 2006). Most
mouse EAE models require additional injection of pertussis
toxin. The underlying theory is that mycobacterial compo-
nents in the adjuvant provide the requisite “danger” context
for the autoantigen to break tolerance and to activate signaling
pathways in innate and adaptive immune cells that lead to the
induction of an autoimmune process (Mills 2011). However,
the bacterial antigens in CFA skew the response of T cells
towards Th1, whereas in the absence of bacterial components,
a Th2 response is observed (Billiau andMatthys 2001). CFA is
also notorious for causing severe granulomatous skin reactions
at the injection sites causing serious animal discomfort. These
ethical concerns as well as conceptual arguments have
prompted us to examine whether CFA can be replaced by
the much milder incomplete Freund’s adjuvant (IFA). IFA
provides an oil-in-water depot for the (auto) antigen, but
lacks bacterial antigens. We tested this in three different
NHP species from captive colonies: two Old World spe-
cies, the rhesus monkey (Macaca mulatta) and the
cynomolgus monkey (Macaca fascicularis), and one New
World monkey species, the common marmoset (Callithrix
jacchus).
Despite several attempts, an EAE model displaying satis-
factory similarity with MS could not be established in rhesus
macaques, as all immunization protocols tested thus far
induced acute disease with seriously destructive CNS pa-
thology, which more closely resembled acute disseminated
encephalomyelitis (ADEM) than MS (reviewed in ('t Hart
et al. 2005)). Although we have no prior experience with
EAE in cynomolgus macaques, literature data suggest that
they develop a similar type of acute inflammatory disease as
rhesus macaques (Nam 2000), possibly slightly less acute
(Ma et al. 2009).
In the past 15 years we have tested a variety of EAE
induction protocols in the marmoset monkey (reviewed in
('t Hart and Massacesi 2009)). The clinical and pathological
characteristics of these models have been unraveled in sub-
stantial detail (reviewed in ('t Hart and Massacesi 2009)) and
were found to share relevant characteristics with MS. Recent
studies in marmosets have all been performed with rhMOG
or the immunodominant peptide MOG34−56. The aminoacid
sequence of MOG is highly conserved between human,
mouse, macaques and marmoset monkeys (Delarasse et al.
2006). Identical epitopes are found to be immunodominant in
each of the species (von Budingen et al. 2004; Brok et al.
2007). rhMOG andMOG34−56 were used in combination with
one of two adjuvants: CFA and IFA. The investigated combi-
nations (rhMOG/CFA, MOG34−56/CFA, MOG34−56/IFA) all
gave a consistent disease induction, with slight differences
regarding disease onset and duration (Brok et al. 2000; Kap
et al. 2008; Jagessar et al. 2010).
The finding that clinically evident EAE could be induced
with MOG34−56/IFA (Jagessar et al. 2010) shows that the
classical dogma for SPF mice that the induction of autoim-
munity in animals depends on danger signals, may not apply
to NHP. The primary aim of the current study was therefore
to test whether EAE could be induced with the more com-
plex rhMOG protein. We hypothesized that the rhMOG/IFA
induction protocol would lead to anti-rhMOG T- and B-cells
responses, whereas anti-rhMOG B-cell responses were ab-
sent in the MOG34−56/IFA model (Jagessar et al. 2010).
We describe here the induction of EAE in the three NHP
species, using rhMOG formulated in IFA. The studies were
performed at two locations, namely the Biomedical Primate
Research Centre (BPRC, Rijswijk, The Netherlands) and
1252 J Neuroimmune Pharmacol (2013) 8:1251–1264
MIRCen (Fontenay-aux-Roses, France). The results show
that clinically evident EAE could be induced in all three
species presenting clinical and pathological features reminis-
cent of MS, although EAE developed at a different incidence
and severity. Moreover, it is now possible to interrogate the
non-human primate system for the presence and profile of
encephalitogenic T cells without the bias of bacterial anti-
gens skewing the response of activated T cells towards Th1
(Billiau and Matthys 2001).
Materials and methods
Innate immune stimulatory activity of rhMOG
rhMOGwas produced in E. coli as an unglycosylated protein
encompassing the extracellular domain (amino acids 1–125)
of MOG and was purified as described previously (Kerlero
de Rosbo et al. 1997). rhMOG was screened for contamina-
tion with innate immune antigen receptor ligands. Human
endothelial kidney (HEK293) cell lines were stably
transfected with the Toll-like receptors (TLR) and the nucle-
otide oligomerization domain receptor 2 (NOD2), as previ-
ously described (Jagessar et al. 2010). As a positive control
for NF-κB-mediated activation 25 ng/ml TNF-α (Peprotech,
London, UK) was used. Positive controls for TLR2 were
0.5 μg/ml synthetic diacylated lipoprotein (FSL-1) and 500-
ng/ml LPS (L8274, Sigma-Aldrich, Zwijndrecht, The
Netherlands), for TLR3: 0.25 μg/ml polyriboinosinic
polyribocytidylic acid (Poly (I:C)), for TLR4: 500 ng/ml
LPS, for TLR5: 0.5 μg/ml flagellin, for TLR7: 10 μg/ml of
an adenine analogue (CL-264), for TLR8: 1 μg/ml of a
thiozoloquinolone derivate (CL-075), for TLR9: 5 μM of
synthetic oligonucleotides that contain unmethylated CpG
(ODN2006), for NOD2: 1 μg/ml Muramyldipeptide (MDP).
No ligands are known for TLR10, but TLR10 expression
was confirmed by Western blot (data not shown). All ligands
were obtained from InvivoGen (San Diego, CA), except
LPS, which was obtained from Sigma-Aldrich.
Ethics statement and animals
The EAE experiments in rhesus macaques and marmosets
were performed at the BPRC, (Rijswijk, The Netherlands).
The EAE study in cynomolgus macaques was performed at
the MIRCen NHP research facility (Fontenay-aux-Roses,
France) with support from BPRC staff. Individual data of
the monkeys used are listed in Table 1.
BPRC Five adult male rhesus monkeys of Chinese origin
were imported from a licensed breeder (R.C. Hartelust BV,
Tilburg, The Netherlands), import permits were obtained and
Table 1 Individual data of ani-
mals used in the study
a At the start of the experiment;
age in years for rhesus and
cynomolgus monkeys, in months
for marmosets. Weight in gram
Animal ID Code Agea Weighta Sex Geographical origin
Rhesus monkeys (BPRC)
Ri9805013 R1 12.4 9300 M China
Ri0106111 R2 9.3 12500 M China
Ri970621 R3 13.3 8300 M China
Ri950209 R4 15.6 11800 M China
Ri9604157 R5 14.5 8200 M China
Cynomolgus monkeys (MIRCen)
First experiment
AQ163 C1 7.0 7700 M Mauritius
L9 C2 7.0 3100 F Philippines
Second experiment
AP048 C3 7.9 6100 M Mauritius
L6 C4 7.7 3200 F China
AP770 C5 7.8 8900 M Mauritius
21013 C6 8.0 3400 F Mauritius
Marmoset monkeys (BPRC)
M09064 M1 27 344 F Brasil
M08119 M2 33 367 F Brasil
M09047 M3 28 385 F Brasil
M08093 M4 36 400 F Brasil
M09083 M5 26 357 F Brasil
M08001 M6 43 433 F Brasil
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animals were housed at the BPRC. Six adult female marmo-
sets were randomly selected from the purpose-bred colony
housed at the BPRC. All procedures were performed in com-
pliance with guidelines of the Institutional Animal Care and
Use Committee (IACUC) of the Biomedical Primate Research
Centre (BPRC) in accordance with Dutch law. The rhesus
monkey study was approved by the IACUC under permit
number DEC#648. The marmoset monkey study was ap-
proved by the IACUC under permit number DEC#674.
BPRC’s policy on the welfare of experimental animals can
be found at http://www.bprc.nl/en/animal-welfare/. Before in-
clusion in the study, the monkeys underwent a complete
physical, hematologic, and biochemical examination. They
remained under veterinary care during the study. Rhesus mon-
keys were housed single, but all in one room, and were
provided with cage enrichment, consisting of tennis balls,
mirrors and toys. Marmoset monkeys were pair-housed in
spacious cages enriched with branches and toys and with
padded shelter provided on the floor. The daily diet consisted
of commercial food pellets for, respectively, OldWorld monkeys
(Sniff, Soest, Germany) or for New World monkeys (Special
Diet Services, Witham, Essex, UK), each supplemented with
rice, raisins, peanuts, and fresh fruit, divided over several times
a day. Food treats were often provided in food puzzles.
Marmosets additionally received biscuits, marshmallows, grass-
hoppers, and maggots. Drinking water was provided ad libitum.
Animals were observed daily for signs of discomfort and suffer-
ing. When EAE symptoms were noted, the frequency of obser-
vation was increased to minimally three times per day. Rhesus
monkey handling was performed under ketamine sedation. Most
marmoset handlings were, after training of the animals,
performed without sedation. When handling required sedation,
alfaxalone was used. Animals were sacrificed by an overdose of
barbiturate pentobarbital.
MIRCen Six adult cynomolgus monkeys were selected from
the MIRCen colony. MIRCen animals were purpose-bred
animals from Chinese or Philippine origins raised in at
MIRCen or imported F1 from a primate center on Mauritius
(Noveprim, Le Tamarinier LTD, Mauritius). Following EC
2010/63 and French regulations the project was performed in
an agreed user establishment (agreement nb 92 032 01).
Institutional permission (personal authorization nb 75–739
was obtained for this project from the National Animal
Welfare Office of the French Ministry of Agriculture after
evaluation by the competent evaluation body of the ministry).
All procedures were performed in compliance with animal
welfare body of MIRCEN's user establishment. The monkeys
underwent a complete physical, hematologic, and biochemical
examination before inclusion in the study. They remained
under animal welfare officer (veterinary) of MIRCen center
survey and care during the study. They were housed single,
but cages allowed visual, vocal and direct tactile contact
favoring the social interactions. Cage enrichment was com-
patible with the conditions of the experiments and included
the presence of different materials (woods and plastic toys)
and structures (perching barrels). Feeding enrichment includ-
ed the type of food supplied, and its spatial and temporal
distribution. The daily diet consisted of commercial food
pellets for Old World monkeys (SAFE, France), each
supplemented with rice, peanuts, and fresh fruit, divided over
several times a day in different parts of the cages. Drinking
water was provided ad libitum. Animals were double blind
observed daily for signs of discomfort and suffering. When
EAE symptoms were noted, the frequency of observation was
increased tominimally three times per day. Most handling was
performed, after training without sedation. When handling
required sedation, ketamin was used. Animals were sacrificed
by an overdose of barbiturate pentobarbital.
EAE induction and disease monitoring
IFAwas purchased from Difco Laboratories (Detroit MI) for
immunization of rhesus monkeys and marmosets and from
Sigma-Aldrich (St Quentin Fallavier, France) for immuniza-
tion of cynomolgus monkeys. The immunogen preparations
for immunization of a rhesus or cynomolgus macaque were
prepared by dissolving 300 μg rhMOG in 300 μl PBS,
emulsified with an equal volume of IFA. The emulsion was
injected into the dorsal skin (intradermal route) distributed
over 6 spots of 100 μl each. The immunogen preparation for
marmosets was prepared by dissolving 100 μg rhMOG in
200 μl PBS and emulsified with an equal volume of IFA. The
400 μl emulsion was injected into the dorsal skin (intrader-
mal route) distributed over 4 spots of 100 μl each. All
rhMOG-adjuvant emulsions were prepared by gently stirring
for at least 1 h. Immunizations were repeated approximately
every 28 days until clinical signs were diagnosed (Table 2).
Effectively, rhesus monkey R1 was immunized on day 0, R2
and R3 on days 0 and 28, and monkeys R4 and R5 were
additionally immunized on post immunization day (pid) 56
and 84. Cynomolgus monkeys C1 and C2 were immunized
on days 0, 28, 56 and 188; C2 was additionally immunized
on pid 273. C3 and C4 were immunized only once (day 0)
and C5 and C6 were immunized on days 0 and 26.
Marmosets M1, M2, M3 and M4 were immunized on days
0 and 28 and M5 and M6 were additionally immunized on
pid 84.
Monkeys were observed at least once daily in their home
cage, starting before immunization until the end of the experi-
ment. Clinical signs were scored using a semi-quantitative scale
(Kerlero de Rosbo et al. 2000): 0 = no clinical signs; 0.5 = loss
of appetite, vomiting; 1 = substantial reduction of general
condition; 2 = ataxia, sensory loss and/or visual problems;
2.5 = incomplete paralysis of one (hemiparesis) or two sides
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(paraparesis); 3 = complete paralysis of one (hemiplegia) of
two sides (paraplegia); 4 = complete paralysis (quadriplegia);
5 = moribund. Maximum cumulative discomfort scores have
been defined as the end of the experimentation (euthanasia).
Termination of an animal was decided when it showed signs
of clinical grade 2.5 or 3 during more than 3 days, signs of
clinical grade 4 during more than 18 h and clinical signs of
grade 5 for more than 1 h.
Histology
Rhesus and marmoset monkey brains and spinal cords were
immersion-fixed in 4 % buffered formalin and then trans-
ferred to PBS. Marmoset brains were sectioned in 6–7 slices
while from rhesus brains three samples were excised from
standardized regions of each brain. Next, brain slices were
embedded in paraffin. Cynomolgus monkey brains were
sampled after intracardiac perfusion with PBS and 4 %
PFA and were post-fixed by overnight immersion in 4 %
PFA and then transferred to PBS and embedded in paraffin.
The brain of the animal found dead (C5) was immersed in
4 % buffered formalin during 3 weeks and then transferred to
PBS until processing into paraffin.
For histochemical analysis 3–5 μm-thick paraffin sections
were cut, deparaffinized and stained with the following
histochemical stains: Haematoxylin/Eosin (HE; inflamma-
tion), Luxol Fast Blue/Periodic Acid Schiff (LFB/PAS;
demyelination).
Immunohistology
Immunohistochemical staining on paraffin sections of regions
of interest were then performed to characterize lymphocyte
subtypes (CD3, CD20) and macrophages (MRP8 or
MRP14). Tissues from all three species were stained with
anti-CD3 (A0452, Dako; dilution 1/100) and anti-CD20
(M0755, Dako; dilution 1/200). Rhesus and marmoset tissues
were additionally stained with MRP-14 (BMA Biomedicals,
Switzerland) and anti-PLP (Serotec, MCA839G, UK).
Cynomolgus tissues were additionally stained with anti-
MRP8 (AB92331, Abcam; dilution 1/1000), and anti-PLP
(Sc-58571, Santa-Cruz, dilution 1/100).
Anti-rhMOG antibodies
Serum or plasma samples were collected prior to EAE induc-
tion, at several time points thereafter, and at necropsy.
Samples were tested by ELISA in 96-well microtiter plates
for the presence of antibodies against rhMOG. Plates were
filled with 100 μl per well of rhMOG (5 μg/ml) and incubated
Table 2 EAE induction, time of
EAE onset and euthanasia Animal ID Immunizations (Days) EAE onset Dead/Euthanasia
Day Score Day Score
Rhesus monkeys
R1 0 – – 28 0
R2 0, 28 40 2 41 4
R3 0, 28 46 2.5 48 3
R4 0, 28, 56, 84 – – 106 0
R5 0, 28, 56, 84 – – 111 0
Cynomolgus monkeys
First experiment
C1 0, 28, 56, 188 211 2 215 2
C2 0, 28, 56, 188, 273 67 2 289 5
Second experiment
C3 0 11 1 14 4
C4 0 27 0.5 29 4
C5 0, 26 30 2 32 4
C6 0, 26 41 1 42 2.5
Marmoset monkeys
M1 0, 28 50 2 57 3
M2 0, 28 54 2 57 3
M3 0, 28 56 2 65 3
M4 0, 28 72 2 81 3
M5 0, 28, 84 107 2 111 2.5
M6 0, 28, 84 52 2 114 0
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overnight at 4 °C. After washing and blocking with PBS/1 %
BSA the wells were incubated in duplicate with 1:100 or
1:1000 diluted sample. Bound rhesus or cynomolgus monkey
antibodies were detected with alkaline phosphate-labeled
goat-anti-human IgG (1:2000, AHI1305, Invitrogen/Life
Technologies, Bleiswijk, The Netherlands) or alkaline
phosphate-labeled goat-anti-human IgM (1:10000, A9794,
Sigma, Zwijndrecht, The Netherlands). Marmoset antibodies
were detected with alkaline phosphatase-labeled rabbit-anti-
human IgG (1:2000, Abcam, Cambridge, UK) or alkaline
phosphatase-labeled goat-anti-monkey IgM (1:2000,
Rockland Immunochemicals, Gelbertsville, PA). Conjugate
binding was quantified with p-nitrophenyl phosphate
(Sigma). OD values of rhesus and cynomolgus data were
converted to arbitrary units (AU) using the same positive
control on all plates as reference. Marmoset OD values are
expressed as fold increase relative to pre-immune plasma of
the same monkey.
Results
Innate immune stimulatory activity of rhMOG
Innate immune stimulatory activity in the rhMOG prepara-
tion was assayed by testing its ability to stimulate HEK293
cells expressing human TLRs (TLR2, 3, 4, 5, 7, 8, 9, and 10)
or the NOD2 receptor (Fig. 1). The activation of these
receptors was determined by increased expression of the
NF-κB-driven luciferase reporter gene in HEK293
transfected cells. The rhMOG preparation showed dose-
dependent stimulation via TLR2, and a slight stimulation
(fold increase of ±2.4) via TLR4 by the highest rhMOG
concentration was observed. The remaining TLRs, TLR3,
5, 7, 8, 9, and 10, and the NOD2 receptor did not show a
response upon exposure to rhMOG. IFA did not provide any
ligands for TLR2, 3, 4, 5, 7, 8, 9, and 10 (Jagessar et al.
2010). These data suggest that the rhMOG/IFA immuniza-
tion protocol provides TLR2-restricted innate immune stim-
ulation. However, the serious granuloma formation normally
seen with CFAwas not observed with the current protocol.
Clinical symptoms in actively induced EAE
Rhesus monkeys Five unrelated rhesus monkeys (Table 1)
were immunized with rhMOG/IFA (Table 2). Overt clinical
EAE was observed only in two animals (R2 and R3). EAE
symptoms (visual problems and lethargy, EAE score 2,
Table 2) were first observed in animal R2 on pid 40, which
was 12 days after the second immunization. The EAE symp-
toms worsened at the same fast rate as in the rhMOG/CFA
model. Therefore we chose to euthanize this monkey within
24 h (Fig. 2a). On the day of euthanasia (pid 41) R2 showed
symptoms of complete paralysis of all 4 limbs (score 4).
Animal R3 showed the first clinical signs of EAE (left sided
incomplete paralysis, score 2.5) on pid 46. Its condition
remained stable during the next day, but worsened on pid
48, reaching complete paralysis from below the waist (score
3) and euthanasia was indicated. One animal without EAE
symptoms (R1) did not recover from sedation on day 28. The
remaining two monkeys (R4 and R5) never displayed clini-
cal symptoms of EAE even after 4 immunizations, and were
euthanized around pid 110.
Cynomolgus monkeys Six unrelated cynomolgus monkeys
(Table 1) were immunized with rhMOG/IFA (Table 2) in two
separate experiments, 8 months apart and all developed
EAE. In the first experiment, monkeys C1 and C2 developed
a protracted EAE course (Fig. 2b). Animal C1 showed the first
clinical signs of EAE (paresis) on pid 211, 23 days after the
fourth immunization. The severity of the clinical signs
remained mild during 5 days (from grade 2 to grade 2.5).
Although the clinical state did not worsen, we decided to
euthanize this animal for histological examination. Animal
C2 developed a first EAE episode on pid 67 (11 days after
the third immunization) with ataxia and tremors (grade 2). The
clinical signs remained stable for 16 days but then disappeared.
Seventeen days after onset this animal had recovered
completely. A second bout of clinical signs was observed on
pid 286 (13 days after the fifth immunization) with paresis
(score 2) progressing within 2 days to a moribund state.
In the second experiment, EAE was induced in four
additional monkeys, which all developed a similar acute
EAE beginning either after the first immunization for C3
(pid 11) and C4 (pid 25) or after the second immunization for
C5 (pid 30, 4 days after the second immunization) and C6
(pid 41, 15 days after the second immunization). The clinical
signs in these animals started with ataxia (C4) or paresis (C3,
C5) or both (C6) progressing in 2 or 3 days to quadriplegia or
paralysis leading to euthanasia (C3, C4, C6) or death (C5)
when the process evolved too fast.
Common marmosets Six unrelated common marmosets were
immunized at 28-day intervals with rhMOG/IFA. Overt clin-
ical EAE was observed in all six animals (Fig. 2c). Four
monkeys received a total of two immunizations, after which
all developed EAE (M1, M2, M3, M4). The disease durations
from onset to the ethical end-point clinical score 3.0
(paralysis) in these animals were respectively: M1 pid 50–
57, M2 pid 54–57, M3 pid, 56–65 and M4 pid 72–81.
Monkey M5 developed neurological signs after three immu-
nizations (pid 107), reaching a maximum EAE score of 2.5
(paresis of two hind limbs). Noteworthy is that the disease
presentation in M5 differed from the other 5 monkeys. The
hind limbs displayed signs of spastic paresis, and the fore
limbs were weak. M5 was euthanised with score 2.5
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(hemiparesis) at pid 110. Monkey M6 displayed only a short
period of clinically evident EAE (ataxia, score 2) after the
second immunization (pid 52) and went into remission. A
third immunization with the same antigen preparation did
Fig. 1 Stimulation of innate
immune activity by rhMOG.
TLR and NOD2 stimulatory
activity of rhMOG was tested in
HEK293 cell lines stably
transfected with human TLR2,
3, 4, 5, 7, 8, 9, and 10 or NOD2.
Cell lines were incubated with a
dose titration of rhMOG.
Positive controls comprised
stimulation with the specific
TLR and NOD2 ligands. Data is
expressed as fold increase of
bioluminescence (mean ± SEM)
relative to unstimulated cells.
Fold increase above 2 was
considered positive
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not induce a relapse; this monkey was sacrificed without
clinical symptoms at pid 114.
In conclusion, in all three species a variable clinical presen-
tation of EAE inducedwith rhMOG/IFAwas observed. Clinical
non-responders were only observed in rhesus monkeys.
Histology of the brain and spinal cord
Rhesus monkeys (Fig. 3) Similar to the EAE models induced
with myelin, rhMBP or rhMOG in CFA, pathological
changes observed after rhMOG/IFA immunizations were
characterized by edema, severe inflammation and demyelin-
ation, mainly localized in the brain (Fig. 3a–c, g–j). In the
brains of the two monkeys that did present clinically evident
EAE (R2 and R3) large-sized demyelinated areas were ob-
served. Lesion infiltrates contained T and B lymphocytes
(Fig. 3d, e) mainly organized in perivascular cuffs as well
as MRP14+ monocytes and granulocytes (Fig. 3f) infiltrat-
ing the CNS parenchyma. Some of these lesions were hem-
orrhagic and contained mainly neutrophilic granulocytes
(PMNs, Fig. 3g–j). The spinal cord of these monkeys
contained some smaller-sized infiltrates (not shown). In
monkey R1, which did not recover from anesthesia at pid
28, small perivascular infiltrates were found in the white
matter parenchyma of brain and spinal cord (not shown). In
the two rhesus monkeys that did not develop overt clinical
signs (R4 and R5), no histological signs of inflammation or
demyelination could be found (not shown).
Cynomolgus monkeys (Fig. 4) Different from rhesus mon-
keys, EAE-affected cynomolgus monkeys displayed various
types of lesions in the brain and the spinal cord. Monkey C1
which displayed late onset EAE (pid 211), presented a unilat-
eral subacute demyelinated lesion in the subcortical white
matter (frontal lobe) (Fig. 4a–f), characterized by the presence
of perivascular macrophages and a low number of CD3+ and
CD20+ lymphocytes. At the periphery of the lesion, MRP8+
macrophages containing intracytoplasmic LFB+/PLP + mye-
lin degradation products were also found. Macrophages in the
lesion center contained either PAS+, and/or LFB + myelin
degradation products associated with loss of MRP8 reactivity,
indicating early active to late active demyelination. Monkey
C2 presented two types of lesions (Fig. 4g–k). First, a large
subacute lesion was observed in the left frontal and parietal
lobe associated with edema and swelling of the left hemi-
sphere. This lesion was composed of a large demyelinated
center containing LFB+, PAS + and MRP8- macrophages
indicating early active to late active demyelination. Near the
fornix, large coalescing perivascular cuffs of neutrophils and
macrophages associated with few CD3 and CD20 lympho-
cytes were observed. In the cerebellar white matter a large
demyelinated lesion was observed, surrounded by a few
sparse pale and thin myelin sheaths, suggestive of
remyelination. The presence of PAS, PLP and LFB negative
macrophages indicated that this was an inactive demyelinated
lesion. At the periphery of the lesion, two encapsulated gran-
ulomas containing PAS + macrophages were noted.
Monkeys immunized in the second experiment all
presented large areas of neutrophil infiltration, necrosis, hem-
orrhages and demyelination (Fig. 3i). These lesions contained
perivascular and MRP8+ macrophages, which contained
PLP + and Luxol + myelin degradation products (active
demyelination) associated with a lower number of CD3+ T
lymphocytes and very few CD20+ B lymphocytes. In these
animals a limited number of large lesions with the same
features as in the brain were also observed in the spinal cord.
Common marmosets (Fig. 5) In all five monkeys that
presented clinically evident EAE at the time of necropsy,
Fig. 2 Clinical expression of EAE induced by rhMOG/IFA in three
NHP species. EAE was induced in (a) rhesus monkeys (n=5), (b)
cynomolgus monkeys (n=6) and (c) common marmosets (n=6) by
immunization with rhMOG emulsified in IFA. EAE symptoms were
observed in only two rhesus monkeys. One animal died at anesthesia on
pid 28. All six cynomolgus monkeys and all six marmoset monkeys
developed EAE (score ≥2)
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we observed presence of inflammation and demyelination in
the brain and spinal cord, although the severity varied be-
tween individual cases. In the CNS, demyelinating lesions
were present in large white matter tracts such as corpus
callosum and optic tract (Fig. 5a–d). In addition demyelin-
ation was seen in cortical regions. All three lesion types
defined in MS (subpial, intracortical and leukocortical) were
found. Subpial lesions in these animals were inactive and
showed minor PLP + degradation products in microglial
cells at the border of the lesions. Similar to MS subpial
demyelinating lesions (Lucchinetti et al. 2011), the corre-
sponding meninges contained dense infiltrates of lympho-
cytes and macrophages (Fig. 5e). Intracortical lesions with
an inactive core and late active rim with PLP + macrophages
were regularly found (Fig. 5f). In the one monkey that
displayed only a short period of ataxic problems but was
healthy at the time of necropsy, no histological abnormalities
were found (not shown). Thus, a close correlation exists
between the presence of histological and neurological
abnormalities.
Anti-rhMOG antibodies
We determined anti-rhMOG antibody levels in serum or
plasma. To this end, samples collected at regular intervals
and at necropsy were tested for the presence of IgM and IgG
binding to rhMOG (Fig. 6), being the most relevant speci-
ficity for mediating demyelination (Menge et al. 2007).
Rhesus monkeys A clear dichotomy between the animals that
developed EAE and those that did not was observed for anti-
Fig. 3 Histology of the rhMOGF/IFA model in rhesus monkeys. a–f
Early demyelinating lesion in the brain of rhesus monkey R3. a Staining
for LFB/PAS (bar: 5 mm). Border of the lesion is indicated by red dots.
The rectangle frames part of the lesion enlarged in panel B. b The
border of the lesion is indicated by red dots. A large blood vessel is seen
in the center (bar: 500 μm). Left from the vessel is a grey matter area
(GM) while the area on the right displays extensive edema. The rect-
angle shows the area enlarged in panel c. c This panel shows the center
of the demyelinating lesion (bar: 100 μm). Arrowheads point at mac-
rophages with LFB + myelin degradation products. The insert shows an
HE stain of cells in the perivascular cuff. Arrowheads point at eosino-
philic granulocytes. d–f The same blood vessel as seen in panel c is
shown. d Staining for CD3 shows lymphocytes in the perivascular
space and in the surrounding parenchyma (arrowheads) (bar: 50 μm).
e Staining for CD20 shows B cells in the perivascular space (bar:
50 μm) but not in the surrounding parenchyma. f Staining for MRP14
shows macrophages and activated microglia in the perivascular space
and deeply infiltrated in the surrounding parenchyma (bar: 50 μm). g–j
Large hemorrhagic lesions are visible in the brain of R2. g LFB/PAS
stains (bar: 5 mm). Lesions are indicated by the rectangles. h Lesions
can be seen more clearly in the HE staining (bar: 5 mm). The area in the
rectangle is enlarged in panel i. i The lesion consists of large numbers of
PMN (blue) mixed with erythrocytes (red, bar 500 μm). In the insert,
individual PMN and erythrocytes can be seen. j MRP14 staining dem-
onstrating both MRP14+ PMN and macrophages (bar 50 μm)
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rhMOG IgM and IgG levels in the serum. High levels of IgM
antibodies were detected already on pid 14 in monkeys that
displayed clinical signs of EAE (R2 and R3), which exceeded
the titers measured in the other animals several fold (Fig. 6a).
The IgG levels were also already higher in these two monkeys
on pid 14 as compared to the other monkeys, peaking around
disease onset and exceeding the levels in the disease free
monkeys between 10 and 500 fold (Fig. 6b). Monkey R1,
which died at anesthesia on pid 28 had similar IgM and IgG
levels as the other two monkeys without EAE.
Cynomolgus monkeys Similar to what was observed in the
rhesus monkeys, anti-rhMOG IgM rose sharply in the case of
acute outcome in the cynomolgusmodel as well, but remained
low or absent in cases with protracted EAE. Early high plasma
levels of anti-rhMOG IgM antibodies were present only in the
four monkeys from experiment 2 (C3, C4 and C5, C6), which
developed early EAE, i.e. within 50 days (Fig. 6c). The
monkeys from experiment 1, that developed remitting (C2)
or late (C1) EAE after several immunizations, displayed low-
level IgM antibodies, without an early peak. Unlike in rhesus
monkey, in cynomolgus macaques, variations in the levels of
anti-rhMOG IgG did not seem to correlate with the course of
EAE as elevated anti-rhMOG IgG levels were measured in
C1, C2 and C5 at euthanasia.
Common marmosets IgM antibodies peaked between pid 14
and 28. A correlation between the IgM titer and survival in
marmosets was also observed, similar to both macaque
models. Animals M5 and M6 with the longest survival times
(111 and 114 days), showed no IgM peak between pid 14 and
28. High IgM plasma levelsmeasured inM1,M2 andM4were
instead associated with a faster disease progression. There was
one exception (M3), which did not display an IgM peak, but
was already sacrificed with neurological symptoms at day 65.
Anti-rhMOG IgG levels increased in all animals from pid 28
Fig. 4 Histology of the rhMOGF/IFA model in cynomolgus monkeys.
a–f Lesions in the brain of cynomolgus monkey C1. aOverview with HE
stain (magnification x0.8). The rectangle indicates features of pallor and
inflammation. b Overview with LFB/PAS stain (x0.8). The rectangle
indicates a demyelinated area. cMacrophagic perivascular inflammation
(HE stain, x100). Insert: HE stain, x400. d Macrophages containing
intracytoplasmic LFB + myelin degradation products (x400). Insert:
PLP stain, macrophages. e, f A perivascular cuff is shown (both x400).
e CD3 stain. f CD20 stain. g–k Lesions in the brain of cynomolgus
monkey C2. g Overview with HE stain (x0.8). The rectangle indicates
features of pallor and inflammation. h Overview with LFB/PAS stain
(x0.8). The rectangle indicates a demyelinated area. iMacrophagic infil-
tration (HE stain x400). Note the vacuolated cytoplasm of the macro-
phages. Insert: Macrophages containing PAS + and LFB + myelin deg-
radation products. jOverview of cerebellar white matter (LFB/PAS stain,
x10). Demyelinated area is outlined in black. Insert: Pale luxol staining
associated with remyelination. k Vacuolated macrophages (HE stain,
x100). Insert: PLP immunostaining. Absence of myelin. l Brain of
cynomolgus monkey C4. Macrophagic and neutrophilic dense tissue
infiltrate (HE stain, x100). Insert: MRP8 immunostaining
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onwards, but no correlation between IgG plasma levels and the
EAE course was found. Remarkably, the highest IgG autoan-
tibody reactivity was measured in the monkey with the atypical
EAE presentation (M6).
In conclusion, the acute form of EAE in macaques and
marmosets seems to be characterized by high anti-rhMOG
IgM levels preceding the onset of EAE, whereas this is
absent in animals with the more chronic form of EAE (C1,
C2, M5 andM6), or without EAE (R4, R5, and possibly R1).
Discussion
NHP models are valid for translational research into the
immunological mechanisms that drive MS pathogenesis
('t Hart and Amor 2003). They are particularly useful for
the evaluation of new therapies, which, due to species spec-
ificity cannot be tested in the more commonly available
rodent models ('t Hart et al. 2004). To fulfill the need for a
preclinical model in which new therapies can be evaluated,
EAE models equivalent to those developed in rodents have
been previously implemented in three captive-bred NHP
species, i.e. rhesus and cynomolgus macaques and common
marmosets (for review: ('t Hart et al. 2005)).
Traditionally, EAE has been induced using a myelin anti-
gen formulated in CFA, which in mice is often supplemented
with injection of pertussis toxin. The increasing criticism
against the usage of CFA for the establishment of disease
models in NHP, with regard to the acute fatal outcome and
the serious ulcerative skin lesions formed at the inoculation
sites, motivated us to examine whether EAE could also be
induced with the less immunogenic and less discomforting
IFA.
TLR and NOD-like receptors are two major forms of the
innate immune mechanism that supply immediate responses
against pathogenic disruption e.g. of tissue injury. The acti-
vation of innate immune mechanisms by microbial danger
signals from the adjuvant is commonly regarded as indis-
pensable for EAE induction in rodent models (Darabi et al.
2004; Visser et al. 2005). We are aware of only one exception
to this dogma, i.e. the EAE model in DA rats (Lorentzen
et al. 1995; Lenz et al. 1999).
Our previous work showed that IFA does not contain
ligands for TLRs (Jagessar et al. 2010). In the current study
we tested whether rhMOG contains ligands for TLR2, 3, 4,
5, 7, 8, 9, and 10, and NOD2. We found that rhMOG
stimulates HEK293 cells expressing TLR2 and 4 transgenes
in a dose dependent manner. This TLR2 and 4 activation
may be explained by the fact that rhMOG was produced in
E.coli. Although rhMOG was purified by a TALON® metal
affinity resin (Clontech Laboratories, Inc. CA) and exhaus-
tively dialyzed, it could contain traces of LPS or peptidogly-
can. Responses of the remaining tested TLRs (TLR 3, 5, 7, 8,
9, and 10) and NOD2 transfected cells to stimulation with
rhMOG were absent.
Previous studies in the marmoset showed that replace-
ment of CFA by IFA did not affect the possibility to elicit
Fig. 5 Histology of the rhMOG/IFA model in marmoset monkeys. a–f
Lesions in the brain of marmoset monkey M4. a Right hemisphere
overview (bar: 2.5 mm). Staining for LFB/PAS. Rectangle 1 shows a
large demyelinating lesion in the corpus callosum enlarged in panel B.
Rectangle 2 shows a cortical lesion enlarged in panel E. b Large late
active/inactive demyelination lesion in the corpus callosum (bar:
250 μm). c HE staining shows the same lesion (bar: 250 μm). Insert
shows CD3+ T cells present at the border of the lesion indicated by the
rectangle. d Staining for PLP demonstrates that the center of the lesion is
devoid of myelin and myelin degradation products (bar: 250 μm). The
rectangle at the border of the lesion shows an area with macrophages with
PLP + degradation products (enlarged in the insert). e PLP staining shows
inactive subpial demyelination (bar: 200 μm). The rectangle at the border
of the lesion shows the area enlarged in the insert: a microglial cell with
weak PLP + degradation products. M: arrows point at meningeal in-
filtrates. CC: corpus callosum. f PLP staining shows an intracortical
demyelinating lesion (bar: 250 μm). Rectangle indicates the area with
multiple PLP + macrophages which are enlarged in the insert
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EAE with MOG34−56 (Jagessar et al. 2010). In these studies
minor differences in clinical presentation of the diseases in-
duced with CFA or IFA were observed, although analysis of
the involved T-cell subsets indicated that the MOG34−56/IFA
protocol induced a more Th17 driven disease (Jagessar et al.
2010), while theMOG34−56/CFA is a more Th1 driven disease
(Kap et al. 2008).
The results reported in this study show that the replace-
ment of CFA by IFA substantially reduced either the severity
of EAE in at least part of the cynomolgus monkeys and the
EAE incidence in rhesus monkeys. In common marmosets,
the disease is very similar to the MOG34−56/IFA model.
However, skin reactions at IFA injection sites were much
milder than observed with CFA. Histological examination of
the injection sites in cynomolgus monkey showed only low
grade eosinophilic granuloma-formation containing rhMOG
without skin ulceration (data not shown).
The incidence of EAE induced with rhMOG/IFA was re-
duced in rhesus monkeys as compared to the rhMOG/CFA
model (Kerlero de Rosbo et al. 2000; Haanstra et al. 2013), but
the clinical and pathological features were very similar with
both protocols. In contrast to rhesus monkeys but similar to
marmosets, all immunized cynomolgus monkeys developed
EAE although clinical presentations were variable, with ful-
minant and milder forms. Acute fulminant forms were ob-
served with the same clinical presentation as in rhesus mon-
keys while milder presentations of either a late onset disease
or a relapsing-remitting form were observed in C1 and C2,
respectively. Relapsing-remitting forms of EAE in macaques
were previously described with immunomodulatory treat-
ment (Rose et al. 1987; Shaw et al. 1988; Rose et al. 1991)
but never as a spontaneous course of the disease. Thus, the
substitution of CFA by IFA seems to permit the appearance
of milder chronic forms of EAE. The reasons of variability
of EAE outcome among the cynomolgus monkeys remain
unknown. It could be due to several factors as genotype,
gender, previous infections, antigen repertoire, or individual
microbiome that alone or in combination can determine
onset and modulate EAE or MS development (Ehlers et al.
2010; Berer et al. 2011). In cynomolgus macaques gender
does not explain variability, as acute and mild forms of EAE
were observed in both males and females. Difference of
incidence between rhesus and cynomolgus can be due to
genetic factors favoring resistance to rhMOG/IFA
Fig. 6 Early and/or high level
anti-MOG IgM antibodies
correspond with EAE onset and
severity. Anti-rhMOG IgM (a,
c, e) and IgG (b, d, f) antibodies.
Anti-rhMOG antibodies in (a,
b) rhesus monkeys, (c, d)
cynomolgus monkeys, and (e, f)
marmoset monkeys. Antibodies
in rhesus and cynomolgus
monkeys are expressed as
arbitrary units (AU), which are
identical for both species.
Antibodies in marmosets are
expressed as fold increase
relative to pre-immune plasma.
All monkeys have IgG
antibodies against rhMOG. In
rhesus and cynomolgus
monkeys, early, high titers of
anti-rhMOG IgM antibodies are
limited to animals with acute
onset and/or disease progression
(R2, R3, C3, C4, C5, C6).
Monkeys with early, high anti-
rhMOG IgG antibodies also
have early, high IgM antibodies.
In marmoset monkeys this
correlation is less clear, but
here, the longest surviving
animals (M5 and M6) also have
no IgM antibodies
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immunization. It could also be explained by shorter duration
of the rhesus monkey experiment, although the number of
immunizations is similar. One possible explanation for the
difference between marmosets and rhesus monkeys could be
the different expression of complement regulatory proteins
within lesions (van Beek et al. 2005). The expression of
decay-accelerating factor (DAF, CD55) was not studied in
cynomolgus monkeys.
We observed a remarkable association between EAE sus-
ceptibility and high serum levels of anti-rhMOG IgM anti-
bodies in all three species. Acute responders to the immuni-
zation, characterized by high anti-rhMOG IgM serum or
plasma levels, developed clinical EAE earlier than monkeys
with low or no detectable anti-rhMOG IgM in their serum. In
the rhesus monkey model, early onset of EAE was also
correlated with high IgG titers, which has been described
for MS patients and marmoset monkeys immunized with
myelin in CFA as well (Lalive et al. 2006). Furthermore,
anti-MOG antibodies are more frequently found in patients
with ADEM than with MS (Mader et al. 2011). Moreover,
high titers of anti-MOG autoantibodies are frequently found
in children with early onset inflammatory/demyelinating
disease (McLaughlin et al. 2009).
Association of autoimmune disease susceptibility with
high IgM autoantibody serum levels has also been found in
a well-established autoimmune arthritis model in rhesus
monkeys, namely bovine type II collagen (bCII)-induced
arthritis (CIA) (Bakker et al. 1991). In this CIA model we
were able to demonstrate a causal relation between IgM
autoantibodies against collagen and disease, because inabil-
ity to produce these autoantibodies made the monkeys toler-
ant to CIA induction with native bCII in CFA ('t Hart et al.
1993). The inability to produce anti-collagen IgM autoanti-
bodies was due to one particular MHC class I serotype
(Mamu-B26) in monkeys producing low level anti-bCII
IgM autoantibodies (Bakker et al. 1992). Such an association
between MHC alleles and forms of EAE has not been
described.
In conclusion, we present new and refined EAE models in
three different NHP species. The models are induced with
IFA, which does not contain the mycobacterial components
that are present in CFA. These models are therefore more
animal friendly than the corresponding models induced with
CFA. These CFA-free models are also useful for investigat-
ing subtle adaptive immune mechanisms of disease suscep-
tibility or resistance.
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